NEW YORK (GenomeWeb News) – Roche today reported that first-half 2010 sales for its diagnostics division increased 7 percent, with its applied science unit posting 11 percent growth for the period.
The Swiss pharmaceuticals, diagnostics, and research products giant reported overall revenues of CHF 24.64 billion ($23.6 billion), up 3 percent from CHF 24.01 billion for the first half of 2009.
Its diagnostics division had 7 percent sales growth to CHF 5.25 billion, with tissue diagnostics and applied science providing the strongest growth at 13 percent and 11 percent, respectively. The firm's molecular diagnostics sales increased 2 percent to CHF 604 million.
Roche said that within its applied science business, cell analysis products had particularly strong growth. The firm did not mention its sequencing products sales in a statement accompanying its financial results.
Roche's pharmaceutical sales were up 1 percent for the period at CHF 19.39 billion.
Overall, Roche's net income for the first half was up 37 percent at CHF 5.56 billion, or CHF 6.91 per share, from CHF 4.05 billion, or CHF 6.32 per share.